$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414047772 Filed on August 07, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$8.214M	$8.259M	$3.531M
YoY Change	71.05%	133.9%	-50.29%
Cost Of Revenue	$4.027M	$5.102M	$1.632M
YoY Change	76.93%	212.62%	-68.11%
Gross Profit	$4.187M	$3.157M	$1.899M
YoY Change	65.76%	66.25%	-4.33%
Gross Profit Margin	50.97%	38.22%	53.78%
Selling, General & Admin	$4.800M	$5.800M	$4.000M
YoY Change	23.08%	45.0%	60.0%
% of Gross Profit	114.64%	183.72%	210.64%
Research & Development	$19.22M	$15.20M	$10.79M
YoY Change	37.79%	40.96%	100.8%
% of Gross Profit	459.02%	481.53%	567.93%
Depreciation & Amortization	$1.000M	$1.000M	$600.0K
YoY Change	66.67%	66.67%	50.0%
% of Gross Profit	23.88%	31.68%	31.6%
Operating Expenses	$19.22M	$15.20M	$10.79M
YoY Change	37.79%	40.96%	100.8%
Operating Profit	-$19.79M	-$17.85M	-$12.90M
YoY Change	29.52%	38.4%	120.29%
Interest Expense	$47.00K	$51.00K	$45.00K
YoY Change	-26.56%	13.33%	1400.0%
% of Operating Profit
Other Income/Expense, Net	-$19.00K	$18.00K
YoY Change	90.0%
Pretax Income	-$19.73M	-$17.86M	-$12.63M
YoY Change	28.93%	41.46%	113.31%
Income Tax		$0.00	$5.000K
% Of Pretax Income
Net Earnings	-$19.73M	-$17.86M	-$12.63M
YoY Change	28.93%	41.41%	113.4%
Net Earnings / Revenue	-240.16%	-216.3%	-357.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.655M	-$1.642M	-$1.658M
COMMON SHARES
Basic Shares Outstanding	238.4M shares	209.3M shares	152.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$178.1M	$152.5M	$40.60M
YoY Change	21.65%	275.62%	53.21%
Cash & Equivalents	$34.47M	$103.9M	$2.574M
Short-Term Investments	$143.6M	$149.7M	$38.00M
Other Short-Term Assets	$402.0K	$269.0K	$20.00K
YoY Change	10.14%	1245.0%	-92.34%
Inventory
Prepaid Expenses	$6.395M	$5.116M	$2.024M
Receivables	$2.859M	$3.719M	$907.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$192.0M	$166.6M	$45.37M
YoY Change	23.84%	267.25%	29.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.49M	$15.12M	$13.32M
YoY Change	25.22%	13.54%	71.8%
Goodwill	$56.17M	$57.91M	$33.14M
YoY Change	-4.4%	74.73%	0.0%
Intangibles	$13.76M	$15.09M
YoY Change	-16.1%
Long-Term Investments	$12.20M	$56.40M	$0.00
YoY Change
Other Assets	$159.0K	$159.0K	$335.0K
YoY Change	-3.05%	-52.54%	-4.29%
Total Long-Term Assets	$100.5M	$145.4M	$47.55M
YoY Change	11.64%	205.74%	13.22%
TOTAL ASSETS
Total Short-Term Assets	$192.0M	$166.6M	$45.37M
Total Long-Term Assets	$100.5M	$145.4M	$47.55M
Total Assets	$292.5M	$312.0M	$92.92M
YoY Change	19.36%	235.77%	20.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.975M	$4.495M	$2.946M
YoY Change	-10.9%	52.58%	-12.84%
Accrued Expenses	$13.71M	$11.00M	$7.223M
YoY Change	43.54%	52.26%	28.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$900.0K	$900.0K	$600.0K
YoY Change	28.57%	50.0%
Total Short-Term Liabilities	$18.64M	$17.48M	$11.26M
YoY Change	30.68%	55.29%	19.47%
LONG-TERM LIABILITIES
Long-Term Debt	$700.0K	$900.0K	$1.900M
YoY Change	-63.16%	-52.63%	375.0%
Other Long-Term Liabilities	$1.399M	$1.507M	$10.60M
YoY Change	-11.34%	-85.78%	73.77%
Total Long-Term Liabilities	$1.399M	$1.507M	$12.50M
YoY Change	-11.34%	-87.94%	92.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.64M	$17.48M	$11.26M
Total Long-Term Liabilities	$1.399M	$1.507M	$12.50M
Total Liabilities	$30.86M	$30.26M	$23.69M
YoY Change	8.29%	27.72%	49.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$461.5M	-$441.8M	-$380.8M
YoY Change	16.53%	16.03%	11.05%
Common Stock	$2.389M	$2.386M	$1.532M
YoY Change	14.31%	55.74%	15.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	455.4K shares	455.4K shares	455.4K shares
Shareholders Equity	$261.7M	$281.7M	$69.23M
YoY Change
Total Liabilities & Shareholders Equity	$292.5M	$312.0M	$92.92M
YoY Change	19.36%	235.77%	20.71%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$19.73M	-$17.86M	-$12.63M
YoY Change	28.93%	41.41%	113.4%
Depreciation, Depletion And Amortization	$1.000M	$1.000M	$600.0K
YoY Change	66.67%	66.67%	50.0%
Cash From Operating Activities	-$15.80M	-$11.00M	-$7.600M
YoY Change	6.04%	44.74%	24.59%
INVESTING ACTIVITIES
Capital Expenditures	-$3.100M	-$900.0K	-$1.700M
YoY Change	93.75%	-47.06%	466.67%
Acquisitions
YoY Change
Other Investing Activities	-$51.10M	-$101.8M	-$1.600M
YoY Change	-400.59%	6262.5%	-61.9%
Cash From Investing Activities	-$54.10M	-$102.8M	-$3.200M
YoY Change	-451.3%	3112.5%	-28.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K	107.7M	4.400M
YoY Change	-99.58%	2347.73%	-63.64%
NET CHANGE
Cash From Operating Activities	-15.80M	-11.00M	-7.600M
Cash From Investing Activities	-54.10M	-102.8M	-3.200M
Cash From Financing Activities	500.0K	107.7M	4.400M
Net Change In Cash	-69.40M	-6.100M	-6.400M
YoY Change	-157.93%	-4.69%	-526.67%
FREE CASH FLOW
Cash From Operating Activities	-$15.80M	-$11.00M	-$7.600M
Capital Expenditures	-$3.100M	-$900.0K	-$1.700M
Free Cash Flow	-$12.70M	-$10.10M	-$5.900M
YoY Change	-4.51%	71.19%	1.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3719000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1911000	USD
CY2014Q2	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4839000	USD
CY2013Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	4988000	USD
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	238412649	shares
	dei	Trading Symbol TradingSymbol	NVAX
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	203000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1417000	USD
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	839000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	281731000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	203234000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	311991000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235125000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13597000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-410146000	USD
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	455430	shares
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1004000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7885000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8502000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1507000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	470000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17479000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18122000	USD
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	172000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	195000	USD
CY2014Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	717000	USD
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1293000	USD
CY2014Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	48599000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119471000	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	2386000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	2091000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	724908000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	612900000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-441820000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	238575480	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	238120050	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	209110744	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	208655314	shares
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1568000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	30260000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103857000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	31891000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	271000	USD
CY2014Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	97000	USD
CY2013Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	108000	USD
CY2014Q2	us-gaap	Notes Payable Current NotesPayableCurrent	822000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	877000	USD
CY2014Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1042000	USD
CY2013Q4	us-gaap	Assets Assets	235125000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4495000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5985000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10998000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10411000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	58707000	USD
CY2014Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	758000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	757000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
CY2014Q2	us-gaap	Assets Assets	311991000	USD
CY2014Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	56352000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15124000	USD
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	7241000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14251000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15090000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16250000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	57906000	USD
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5116000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3044000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	269000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	573000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	166602000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-17864000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	145001000	USD
CY2013Q2	us-gaap	Contracts Revenue ContractsRevenue	3276000	USD
	us-gaap	Contracts Revenue ContractsRevenue	12713000	USD
	us-gaap	Contracts Revenue ContractsRevenue	6717000	USD
CY2014Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1018000	USD
CY2013Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	255000	USD
CY2014Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
CY2013Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152312	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	213075	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	150391	shares
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		USD
	us-gaap	Net Income Loss NetIncomeLoss	-22630000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	217178	shares
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-22608000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-12633000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31674000	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-267000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-267000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	615000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-17864000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-12628000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-31674000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	51000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	45000	USD
	us-gaap	Interest Expense InterestExpense	103000	USD
	us-gaap	Interest Expense InterestExpense	68000	USD
CY2014Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	18000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32236000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22902000	USD
CY2014Q2	us-gaap	Investment Income Net InvestmentIncomeNet	20000	USD
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	48000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	32000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	95000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	26110000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	16429000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	47957000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	30267000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17851000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12898000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29720000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20041000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5806000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4012000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10114000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6882000	USD
CY2014Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	5102000	USD
CY2013Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	1632000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	8123000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	3344000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15202000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10785000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	3008000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	648000	USD
CY2014Q2	us-gaap	Revenues Revenues	8259000	USD
CY2013Q2	us-gaap	Revenues Revenues	3531000	USD
	us-gaap	Revenues Revenues	15721000	USD
	us-gaap	Revenues Revenues	7365000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	168000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	207000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	615000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1410000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		USD
CY2013Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12465000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33833000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22423000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax		USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1543000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1383000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	168000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2159000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	207000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19247000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-243000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents		USD
	us-gaap	Interest Paid InterestPaid	100000	USD
	us-gaap	Interest Paid InterestPaid	61000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	171000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17399000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2574000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1823000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-702000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1279000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-40000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-258000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	703000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1214000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-986000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1846000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3157000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	81000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	840000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1026000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	270000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	108868000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11572000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-30000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15614000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14825000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7100000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10018000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1510000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	29000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-338000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-136000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1450000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	13440000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9649000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	104686000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	14754000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-93080000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8181000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31372000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18216000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1828000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-104000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-149000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	245000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	43000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	45000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-458000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2892000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1121000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1956000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	961000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	80000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-232000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4000	USD
CY2014Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	104951000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><p style=" font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in;">Note 1 Organization</p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">Novavax, Inc. (Novavax, and together with its wholly owned subsidiary, Novavax AB, (formerly known as Isconova AB), the Company) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company's product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza and pandemic influenza.</p></div>
CY2014Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	104924000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	34000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1068000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><strong><em>Use of Estimates</em></strong></p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"> </p> <p style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from these estimates.</p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16514230	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15832208	shares
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1068000	USD
CY2014Q2	nvax	Available For Sale Securities Amortized Cost Basis Current AvailableForSaleSecuritiesAmortizedCostBasisCurrent	48577000	USD
CY2014Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	32000000	USD
CY2014Q2	nvax	Available For Sale Securities Amortized Cost Basis Noncurrent AvailableForSaleSecuritiesAmortizedCostBasisNoncurrent	56347000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13597000	USD
CY2014Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	48577000	USD
CY2014Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	48599000	USD
CY2014Q2	nvax	Available For Sale Securities Debt Maturities Rolling Year Two Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoAmortizedCostBasis	56347000	USD
CY2014Q2	nvax	Available For Sale Securities Debt Maturities Rolling Year Two Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoFairValue	56352000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	12981000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	616000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	7000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss		USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	534000	USD
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments		USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1068000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1068000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1068000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5581	pure
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	979000	USD
	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	-801000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	33141000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	33141000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16069000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15090000	USD
	nvax	Remaining Gross Proceeds Sale Of Stock RemainingGrossProceedsSaleOfStock	15000000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31100000	USD
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	16500000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5287	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5581	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5247	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod		shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0133	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0054	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0054	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5381	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6602	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6793	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7372	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0139	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0096	pure
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	13300000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1852000	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	638000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2892000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1121000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	16667	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	16667	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2014Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.20	pure

Files In Submission

Name	View Source	Status
0001144204-14-047772-index-headers.html	Edgar Link	pending
0001144204-14-047772-index.html	Edgar Link	pending
0001144204-14-047772.txt	Edgar Link	pending
0001144204-14-047772-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nvax-20140630.xml	Edgar Link	completed
nvax-20140630.xsd	Edgar Link	pending
nvax-20140630_cal.xml	Edgar Link	unprocessable
nvax-20140630_def.xml	Edgar Link	unprocessable
nvax-20140630_lab.xml	Edgar Link	unprocessable
nvax-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v384836_10q.htm	Edgar Link	pending
v384836_ex31-1.htm	Edgar Link	pending
v384836_ex31-2.htm	Edgar Link	pending
v384836_ex32-1.htm	Edgar Link	pending
v384836_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2014 Q3 Form 10-Q Financial Statement

#000114420414047772 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2014 Q3 Form 10-Q Financial Statement

#000114420414047772 Filed on August 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax